Exposure | Alzheimer disease | |||
Cases | HR (95% CI) | Cases | HR (95% CI) | |
Model 1* | Model 2† | |||
Never use | 546 | 1.00 (ref.) | 438 | 1.00 (ref.) |
Statins‡ | 30 | 0.58 (0.38 to 0.88) | 28 | 0.57 (0.37 to 0.90) |
Lipophilic statins | 25 | 0.55 (0.34 to 0.89) | 23 | 0.54 (0.32 to 0.89) |
Hydrophilic statins | 9 | 0.52 (0.26 to 1.05) | 9 | 0.54 (0.26 to 1.11) |
Non-statin cholesterol-lowering drugs§ | 12 | 1.04 (0.45 to 2.40) | 12 | 1.05 (0.45 to 2.44) |
*Model 1: age, sex-adjusted and use of other lipid-lowering drugs, if applicable.
†Model 2: as Model 1 additionally adjusted education, systolic blood pressure, smoking, total serum cholesterol, body mass index, diabetes mellitus and cardiovascular and cerebrovascular disease.
‡The number of exposed cases for any statin differs from the sum of exposed cases for statin subtypes. This is because persons can contribute exposed person-time to more than one type of statin.
§Fibrates, bile-acid-binding resins or nicotinic acid and derivatives.